LogicBio Therapeutics
Kendall Square
Cambridge
Massachusetts
United States
Tel: 781-771-5579
Website: http://www.logicbio.com/
Email: contact@logicbio.com
About LogicBio Therapeutics
A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney – the company’s core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company’s discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.YEAR FOUNDED:
August 2015
LEADERSHIP:
Founders: Adi Barzel Ph.D., Mark Kay M.D. Ph.D. and Leszek Lisowski Ph.D.
President & CEO: Frederic Chereau
12 articles with LogicBio Therapeutics
-
Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
-
A Look Back at October Life Sciences IPOs
10/31/2018
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month. -
Chardan Serves as Lead Manager for LogicBio Therapeutics
10/22/2018
Chardan announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.
-
LogicBio Therapeutics Appoints Dean Falb, Ph.D., as Chief Scientific Officer
5/23/2018
Genome editing company adds drug development expert in pursuit of breakthrough medicines for pediatric patients
-
LogicBio Therapeutics Launches Development Program in Methylmalonic Acidemia (MMA)
5/9/2018
Preclinical data demonstrate potential for LB-001 to address the underlying cause of MMA
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
LogicBio Therapeutics Strengthens Leadership Team with Key Appointments
5/2/2018
LogicBio Therapeutics, Inc. announced the appointment of Sandra Poole as chief operating officer, and Paul Herzich as senior director of manufacturing.
-
LogicBio Therapeutics Announces Expansion of Leadership Team Through Multiple Key Hires
1/2/2018
LogicBio Therapeutics today announced the expansion of its leadership team with the appointment of four seasoned industry leaders
-
LogicBio Announces $50 Million In Financing To Develop Novel Gene Medicines For Pediatric Patients
6/28/2017
-
Arix Bioscience Leads $45 Million Series B Financing Round Into LogicBio
6/28/2017